Condition: Leukemia · AML · MDS · Sponsor: Cullgen (Shanghai),Inc
The goal of this clinical trial is to learn about the safety of drug CG009301. It also learns if drug CG009301 works to treat in Participants with relapsed or refractory adult haematological malignancies. The main question\[s\] it aims to answer are: 1. To determine the maximum tolerated dose (MTD) and/or objective best dose (OBD) of CG009301 for injection in subjects with relapsed or refractory adult haematological malignancies. 2. To establish subsequent dosing regimens for CG009301 for injection. 3. To characterise the safety profile and tolerability of CG009301 for injection. Participants will Receive treatment with CG009301 until disease progression.
This description comes directly from the study's public registry record.
Xiangyu Jin, MS · +86 13858065096 · xiangyu.jin@cullgen.com
Qiao Yi · qiao.yi@cullgen.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Nanchang University | Nanchang, China | Recruiting |
| The Haematology Hospital of the Chinese Academy of Medical Sciences | Tianjin, China | Recruiting |
| Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology | Wuhan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07347171